Literature DB >> 6205091

The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

H Fujiwara, M Fukuzawa, T Yoshioka, H Nakajima, T Hamaoka.   

Abstract

The present study determines the Ly phenotype of T cells mediating tumor cell rejection in vivo and investigates some of cellular mechanisms involved in the in vivo protective immunity. C3H/HeN mice were immunized to syngeneic X5563 plasmacytoma by intradermal (i.d.) inoculation of viable X5563 tumor cells, followed by the surgical resection of the tumor. Spleen cells from these immune mice were fractionated by treatment with anti-Lyt antibodies plus complement, and each Lyt subpopulation was tested for the reconstituting potential of in vivo protective immunity in syngeneic T cell-depleted mice (B cell mice). When C3H/HeN B cell mice were adoptively transferred with Lyt-1-2+ T cells from the above tumor-immunized mice, these B cell mice exhibited an appreciable cytotoxic T lymphocyte (CTL) response to the X5563 tumor, whereas they failed to resist the i.d. challenge of X5563 tumor cells. In contrast, the adoptive transfer of Lyt-1+2- anti-X5563 immune T cells into B cell mice produced complete protection against the subsequent tumor cell challenge. Although no CTL or antibody response against X5563 tumors was detected in the above tumor-resistant B cell mice, these mice were able to retain Lyt-1+2- T cell-mediated delayed-type hypersensitivity (DTH) responses to the X5563 tumor. These results indicate that Lyt-1+2- T cells depleted of the Lyt-2+ T cell subpopulation containing CTL or CTL precursors are effective in in vivo protective immunity, and that these Lyt-1+2- T cells implement their in vivo anti-tumor activity without inducing CTL or antibody responses. The mechanism(s) by which Lyt-1+2- T cells function in vivo for the implementation of tumor-specific immunity is discussed in the context of DTH responses to the tumor-associated antigens and its related Lyt-1+2- T cell-mediated lymphokine production.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205091

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells.

Authors:  J P Zou; J Shimizu; K Ikegame; H Takiuchi; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  CD4 T cells in tumor immunity.

Authors:  Mara Gerloni; Maurizio Zanetti
Journal:  Springer Semin Immunopathol       Date:  2005-03-15

4.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Immunological memory induced by genetically transduced tumor cells.

Authors:  M M Dar; Z Abdel-Wahab; C E Vervaert; T Darrow; J Barber; H F Seigler
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

6.  Immunotherapy of tumor-bearing mice utilizing virus help.

Authors:  Y Shimizu; K Hasumi; K Masubuchi; Y Okudaira
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells.

Authors:  M Iwashiro; T Kondo; T Shimizu; H Yamagishi; K Takahashi; Y Matsubayashi; T Masuda; A Otaka; N Fujii; A Ishimoto
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Authors:  Assefa Wondimu; Tianqian Zhang; Thomas Kieber-Emmons; Phyllis Gimotty; Katrin Sproesser; Rajasekharan Somasundaram; Soldano Ferrone; Chun-Yen Tsao; Dorothee Herlyn
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

Review 9.  Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.

Authors:  Yolanda Nesbeth; Jose R Conejo-Garcia
Journal:  Clin Dev Immunol       Date:  2010-11-07

Review 10.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.